1949 company foundation
Professor Helmuth Haubold develops and produces vitamin-emulsions (Mulsine), and lays the foundation for Mucos Pharma.
1957 Karl Ransberger, CEO
Karl Ransberger takes over the management in 1957 with four co-workers. In the United States he meets Wiener Professor Max Wolf. Wolf researches in the treatment of cancer, rheumatism, and circulatory and vascular diseases with enzyme combinations. With his colleague, Helen Benitez, he develops the "Wolf-Benitez-Enzymtherapie" and calls the product after the first two letters of both their names: WoBe-Enzyme, which gave birth to the brand name Wobenzym ®!
1960 innovative products for systemic enzyme therapy
The systemic enzyme therapy developed by Professor Max Wolf launches a dynamic innovation phase for Mucos Pharma. The pharmaceutical products Wobenzym ® (for the treatment of inflammation) and WOBE-MUGOS ® (for the treatment of viral infections and tumors) are introduced.
1979 Mucos expands
Mucos Pharma moves to a new and larger facility in Geretsried, 30 km south of Munich.
1991 new products are introduced
Phlogenzym ® (1991) and Mucozym ® (1998) are introduced.
1999 world leader
Production and development facilities in Germany, Europe, USA and Asia provide Mucos Pharma with a production capacity of 3 250 000 tablets per day.
The brand Wobenzym ® expands to Russia and other Eastern European countries. An office is established in Prague.
2005 MVB-Gruppe becomes the new owner of Mucos Pharma
In September of 2005, Peter Mülder becomes the managing director of Mucos Pharma.
2007 Atrium Innovations acquires Mucos
In July 2007, Atrium Innovations, an international company operating from Canada purchases Mucos Pharma. Atrium Innovations is one of the leading companies in the development, manufacture and distribution of cosmetic, pharmaceutical, health & nutraceutical products. Atrium Innovations plans to strengthen Mucos’s already leading position through further development and expansion of its international activities.